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First-line treatment of metastatic renal cell carcinoma still
involves small-molecule tyrosine kinase inhibitors (TKIs)
such as sunitinib and pazopanib, which mainly target the
vascular endothelial growth factor receptor (VEGFR) [1]. It
has recently been shown that two agents improve survival
in second-line treatment. In the METEOR trial [2], cabo-
zantinib, a multikinase inhibitor targeting the VEGFR and
other pathways including MET, RET and AXL, and in the
CheckMate 025 study [3], nivolumab, an immunotherapeu-
tic agent that inhibits the T-cell checkpoint regulator PD-1,
were compared to everolimus and showed a survival
advantage. However the most effective sequence after
first-line TKI treatment is still unknown, so there is a need to
identify factors that predict the response to nivolumab and
cabozantinib. The aim of this letter is to focus on the survival
of patients treated with nivolumab and cabozantinib
according to prior first-line TKI. We used data from
CheckMate 025 and METEOR for a subsequent subgroup
analysis (Table 1) [4,5]. A pooled analysis according to prior
TKI treatment revealed that survival was significantly
improved to a greater extent after prior treatment with
pazopanib (hazard ratio [HR] 0.62, 95% confidence interval
[CI] 0.47–0.82; p = 0.0009) when comparison to sunitinib
(HR 0.76, 95% CI 0.62–0.92; p = 0.005; Fig. 1).
Athough a limitation of this analysis is that literature
data were used rather than a meta-analysis of data for
individual patients, so that definitive conclusions need to be
considered carefully, our data show that cabozantinib and
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Fig. 1 – Subgroup analysis for overall survival among patients receiving nivolumab and cabozantinib according to prior sunitinib or pazopanib.
CI = confidence interval.
2nivolumab seem to reduce the risk of death in patients
treated with prior pazopanib compared with sunitinib.
These data will require further evaluation in prospective
randomized clinical trials.
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Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging
Detects an Early Metabolic Response to Androgen Ablation
Therapy in Prostate Cancer
Rahul Aggarwal *, Daniel B. Vigneron, John Kurhanewicz
Hyperpolarized (HP) 13Cmagnetic resonance spectroscopic
imaging (MRSI) is a novel imaging technique that allows
rapid and noninvasive monitoring of dynamic pathway-
specific metabolic and physiologic processes [1] with
unprecedented gain in sensitivity (10 000–200 000 fold
increase) for imaging of 13C-labeled biomolecules that are
endogenous, nontoxic, and nonradioactive [2,3]. We previ-
ously reported the first-in-human phase 1 clinical study of
HP [13C]-pyruvateMRSI in patients with prostate cancer on
active surveillance, and confirmed the feasibility of
capturing regions of accelerated HP pyruvate-to-lactate
flux in high-grade versus low-grade cancer versus benign
tissue [4].
Here we describe the first results demonstrating the
metabolic response to androgen deprivation therapy (ADT)
using HP [13C]-pyruvate MRSI. The patient presented with
serum prostate-specific antigen (PSA) of 25.2 ng/ml and
Gleason 4 + 5 prostate adenocarcinoma on biopsy.
Cross-sectional imaging demonstrated metastases within
the pelvic nodes and osseous structures. Baseline multi-
parametric (mp) 1H MRI of the prostate (anatomic
imaging, diffusion-weighted imaging [DWI], dynamic
contrast-enhanced [DCE] imaging, and 3D 1H MRSI) with
HP [13C]-pyruvate revealed a bulky tumor involving the left
apex, mid gland, and base peripheral and transition zones,
and right apex, mid gland, and base peripheral zone,
measuring 4.5  1.5  5.1 cm3. T2-weighted MRI showed a
well-defined focus of low signal intensity (T2 score 5/5;
Fig. 1A). The lesion also had marked restricted diffusion
(DWI score 5/5; apparent diffusion coefficient [ADC] 930)
Table 1 – Characteristics of the trials analyzed and data on survival according to prior treatment
Trial Drug Overall survival
Patients (n) Median (mo)
Sunitinib
CheckMate 025 Nivolumab vs everolimus 257 vs 261 23.6 vs 19.8
METEOR Cabozantinib vs everolimus 135 vs 132 Not reported
Pazopanib
CheckMate 025 Nivolumab vs everolimus 126 vs 136 Not reached vs 17.6
METEOR Cabozantinib vs everolimus 88 vs 83 Not reported
